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School, Newcastle upon Tyne NE2 4HH, United Kingdob1,4-Galactosyltransferase 7 (b4GalT7) is a key enzyme initiating glycosaminoglycan (GAG) synthesis.
Based on in vitro and ex vivo kinetics studies and structure-based modelling, we molecularly char-
acterized b4GalT7 mutants linked to the progeroid form of Ehlers–Danlos syndrome (EDS), a severe
connective tissue disorder. Our results revealed that loss of activity upon L206P substitution due to
altered protein folding is the primary cause for the GAG synthesis defect in patients carrying the
compound A186D and L206P mutations. We showed that R270C substitution strongly reduced
b4GalT7 afﬁnity towards xyloside acceptor, thus affecting GAG chains formation. This study estab-
lishes the molecular basis for b4GalT7 defects associated with altered GAG synthesis in EDS.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction such as decorin. Patients harbouring mutations in the B4GALT7Amino acid exchanges in b1,4-galactosyltransferase 7 (b4GalT7,
E.C. 2.4.1.133), which is involved in the synthesis of the glycosami-
noglycan (GAG) linkage region of proteoglycans, are associated
with the pathology of progeroid type Ehlers–Danlos syndrome
(EDS) [1]. EDS forms a group of inherited connective tissue disor-
ders characterized by defects in various extracellular matrix pro-
teins including collagens and small leucine-rich proteoglycans,chemical Societies. Published by E
7; EDS, Ehlers–Danlos syn-
, glucuronic acid; 4-MUX, 4-
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ewcastle University, Medical
m.gene exhibit aged appearance, developmental delay, dwarﬁsm, cra-
niofacial disproportion and general osteopenia [1,2]. In addition,
hypermobile joints, defects in wound healing and loose skin are
observed. Aberrant GAG substitution of decorin was initially de-
scribed in a progeroid EDS patient who carried compound hetero-
zygous amino acid exchanges (A186D/L206P) in b4GalT7 enzyme
[3,4]. More recently, two patients exhibiting typical progeroid
EDS features including craniofacial appearance, skeletal abnormal-
ities, and aged appearance were described [2]. Sequence analysis of
the B4GALT7 gene from these patients revealed a missense muta-
tion causing the substitution R270C. This defect was found to be
associated with reduced galactosyltransferase activity and aber-
rant GAG substitution of decorin and biglycan in cultured skin
ﬁbroblasts [5]. Interestingly, a recent report indicated that in addi-
tion to alterations of the dermatan-sulfate chain of decorin,
changes in the structure of heparan-sulfate proteoglycans may also
contribute to the phenotypic features observed in this b4GalT7-
deﬁcient form of EDS, such as altered cell migration and delayed
wound repair [6].lsevier B.V. All rights reserved.
Table 1
Kinetic parameters of wild-type b4GalT7 and R270C EDS mutant for donor UDP-Gal
and the acceptor 4-MUX.
Enzyme KA (mM) UDP-Gal KB (mM) 4-MUX Kia (mM) kcat (s1)
b4GalT7 0.45 ± 0.09 0.61 ± 0.08 0.09 ± 0.03 1.14
R270C 0.46 ± 0.16 6.12 ± 0.96 0.29 ± 0.09 ND
Kinetic parameters towards donor and acceptor substrates were evaluated by
double substrate kinetics using 0.2 lg puriﬁed GST-b4GalT7 protein at concentra-
tions of UDP-Gal and of 4-MUX varying from 0 to 5 mM. Data were ﬁtted to Eq. (1)
described in Section 2 by non-linear least square regression analysis using the
curve-ﬁtter program of SigmaPlot 9.0. ND, not determined, i.e. no kcat could not be
accurately evaluated for R270C mutant since 4-MUX is poorly soluble at concen-
tration higher than 10 mM required to achieve acceptor substrate saturation.
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normally attached to core proteins to form proteoglycans. These
complex molecules located on the cell surface and in extracellular
matrices of virtually every tissue mediate highly diverse key cell
events, ranging from mechanical support inside and outside cells
to intricate effects on a wide variety of cellular and biochemical
processes, such as blood clotting, cell adhesion, differentiation,
proliferation and motility [7]. These functions depend on interac-
tions of the GAG chains with a variety of molecules including
growth factors, cytokines and their receptors, enzymes such as ma-
trix proteases and coagulation factors, as well as extracellular ma-
trix proteins [8]. The synthesis of GAG chains that govern these
functions is initiated by the formation of a tetrasaccharide linkage
region composed of glucuronic acid-galactose-galactose-xylose
(GlcAb1,3Galb1,3Galb1,4Xyl1-) followed by the elongation of the
two main types of GAGs (i.e. heparin, heparan-sulfate and chon-
droitin-/dermatan-sulfate) [9]. The b4GalT7 enzyme catalyses the
transfer of a galactose (Gal) residue provided by UDP-a-D-Gal
(UDP-Gal) onto Xyl, a key step in the synthesis of the linkage region
of GAG chains [10]. Since the formation of this linker tetrasaccha-
ride is required prior to polymerization of both heparan-sulfate
and dermatan-/chondroitin-sulfate chains, genetic defects of
b4GalT7 strongly affect the biological functions mediated by GAGs,
including tissue development and differentiation, leading to severe
clinical features that are characteristic of the progeria-type variant
forms of EDS [1,2].
Although the alterations in GAG synthesis have been well de-
ﬁned from studies performed in ﬁbroblasts of patients affected
by progeroid form of EDS, the consequences of these gene muta-
tions on b4GalT7 properties have not yet been investigated at the
molecular level. By site-directed mutagenesis and in vitro and
ex vivo kinetic studies, combined to computer-aided modelling
of the human protein structure, we deciphered the mechanisms
by which the A186D, L206P and R270C mutations affect b4GalT7
function and disrupt GAG synthesis pathways in the EDS congeni-
tal glycosylation disorder.2. Materials and methods
2.1. Materials
4-Methylumbelliferyl-b-D-xylopyranoside (4-MUX), UDP-a-D-
galactose (UDP-Gal) were provided by Sigma–Aldrich, and
UDP[14C]Gal and Na2[S35]SO4 was from Perkin–Elmer. The eukary-
otic expression vector pcDNA3.1(+) and competent One Shot
Top10 Escherichia coli cells were from Invitrogen-Fisher Scientiﬁc,
and pET-41a(+) vector and E. coli BL21(DE3) cells were from Nova-
gen-EMD4Biosciences.2.2. Expression vector construction
The human b4GalT7 sequence was cloned as previously de-
scribed [11]. For expression of b4GalT7 in mammalian cells, the
full-length cDNA was modiﬁed by PCR to include a KpnI site and
a Kozak consensus sequence at the 50 end, and a sequence encoding
a myc tag (EQKLIEEDL) and a XbaI site at the 30 end, prior subclon-
ing into the pcDNA3.1(+) to produce pcDNA-b4GalT7. For bacterial
expression, a truncated form of b4GalT7 was expressed as a fusion
protein with glutathione-S-transferase (GST). The sequence lacking
codons for the 60 N-terminal amino acids was ampliﬁed from full-
length cDNA using the corresponding primers including NcoI and
NotI sites and subcloned into the pET-41a(+) vector (Novagen,
EMD4Biosciences) to produce plasmid pET-b4GalT7. Mutations
were generated using the QuickChange II XL site-directed muta-
genesis kit (Stratagene), employing pcDNA-b4GalT7 or pET-b4GalT7 plasmids as template, and sense and antisense primers
listed in Table 1 (Supplementary data).
2.3. Heterologous expression of wild-type and mutated b4GalT7
CHO pgsB-618 cells defective in b4GalT7 activity established by
Esko et al. [12] were purchased from the American Type Culture
Collection (ATCC). Cultured cells were individually transfected at
80% conﬂuency with wild-type and mutated pcDNA-b4GalT7 plas-
mids using ExGen 500 reagent (Euromedex, Souffelweyersheim,
France), according to the manufacturer’s recommendations. Cells
were harvested in phosphate buffered saline (PBS) 48 h after trans-
fection, pelleted by centrifugation at 5000g, resuspended in
0.25 M sucrose, 5 mM HEPES buffer (pH 7.4) and sonicated three-
fold 5 s. Protein concentration was determined by the method of
Bradford [13] prior to SDS–PAGE or activity analyses. Alternatively,
transfected cells were transferred to labelling medium in the pres-
ence of 4-MUX prior to GAG isolation, as described below.
To express wild-type and mutated GST-b4GalT7, E. coli
BL21(DE3) cells harbouring pET-b4GalT7 expression vector were
grown in Luria-Bertani (LB) medium and gene expression was in-
duced with 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG, Sig-
ma–Aldrich) added to bacteria cultured at 20 C for 16 h. GST-
b4GalT7 proteins were puriﬁed by afﬁnity chromatography using
Glutathione Sepharose™ 4B columns (GE Healthcare Life Sciences).
2.4. Galactosyltransferase activity
The in vitro assay of b4GalT7 activity was performed as previ-
ously described [11]. Reactions were performed in 100 mM sodium
cacodylate buffer (pH 7.4) containing 10 mM MnCl2, 1 mM UDP-
Gal, 0.05 lCi UDP[U14C]Gal, 5 mM 4-MUX and 40 lg of total cell
protein or 0.2 lg puriﬁed protein. Incubations were carried out at
37 C for 30–60 min in a total volume of 50 ll, and reaction prod-
ucts were separated by thin layer chromatography [14,15]. For ki-
netic studies, reaction products were analyzed by high
performance liquid chromatography (HPLC) using a reverse phase
C18 column attached to a Waters e2695 instrument equipped with
a Berthold FLowStar radioactivity monitor.
2.5. Kinetic analyses
The kinetic parameters for UDP-Gal and 4-MUX were deter-
mined using double substrate kinetics with concentrations of
UDP-Gal and 4-MUX varying between 0 and 5 mM by non-linear
regression using Sigma Plot™. Data were analyzed for a two-sub-
strate system by ﬁtting to an equation for sequential symmetrical
initial velocity pattern, equation below (ordered or random equi-
libriummechanism) [16,17]. In this equation Vmax is the maximum
velocity, [A] is the concentration of UDP-Gal, and [B] the concen-
tration of 4-MUX. Ka and Kb are the true Km for donor and acceptor
substrates and Kia is the dissociation constant for UDP-Gal.
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Fig. 1. Galactosyltransferase activity of EDS-b4GalT7 mutants expressed in CHO2.6. Analysis of GAG synthesis by Na2[
35S]SO4 incorporation
To analyze GAG chain synthesis initiated from exogenously
added xyloside, CHO pgsB-618 cells transfected with wild-type,
mutant pcDNA-b4GalT7, or empty vector (mock) were incubated
for 12 h in Fischer’s medium containing 10 lCi/ml Na2[35S]SO4 in
the presence or absence of 4-MUX (0–10 lM). Medium (1 ml)
was applied to a G-50 column to separate non-incorporated radio-
labelled sulfate, and GAGs present in the eluates were quantiﬁed
by scintillation counting or resolved by SDS–PAGE using Criterion
Precast gels (4–15% Bis–Tris, Bio-Rad) and visualized by
autoradiography.pgsB-618 towards 4-MUX. Activity of wild-type and mutant enzymes was
evaluated using 5 mM 4-MUX and 1 mM UDP-Gal (0.05 lCi UDP[U14C]Gal) in the
presence of 40 lg cell homogenate. The reaction products were separated by thin
layer chromatography, visualized by autoradiography (shown in inset) and quan-
tiﬁed by scintillation counting. Data are the mean ± S.D. n = 3, *P < 0.05.2.7. Indirect immunoﬂuorescence staining of recombinant CHO pgsB-
618 cells
Indirect immunoﬂuorescence staining of cell surface proteogly-
can GAG chains in CHO pgsB-618 transfected cells was performed
as previously described [18], using mouse anti-heparan-sulfate pri-
mary antibodies (10E4 [19], Seikagaku Corporation) and AlexaFluor
488-conjugated goat anti-mouse secondary antibodies (Molecular
Probes/Invitrogen). Wild-type and mutated b4GalT7 proteins ex-
pressed in CHO pgsB-618 transfected cells were simultanously
immunostained following Triton-X100-permeabilization using
anti-myc primary antibodies and AlexaFluor 594-conjugated goat
anti-mouse secondary antibodies, following the same procedure.2.8. Molecular modelling of human b4GalT7 structure
The molecular model of the human b4GalT7 was built using
Modeller version 8v2 [20], based of the structure of monomer A
of bovine b4GalT1 complexed with UDP-Gal (PDB entry 1O0R)
[21]. The energy of the resulting model was minimized using the
Amber simulation program version 8 [22]. Charges of the atoms
of UDP-Gal were calculated using the GAUSSIAN94 package [23]
and the HF/6-31 G* basis set. Atom-centered charges were ﬁtted
with Antechamber module of Amber 8 [22]. Mn2+ parameters
available from Amber site (http://ambermd.org). Docking of UDP-
Gal–Mn2+ complex in the human b4GalT7 structure was performed
manually based on the position of this ligand in bovine b4GalT1.
The whole system was solvated, the energy was minimized and
submitted to molecular dynamics at 300 K. A model for a O-b-D-
xylosylpeptide corresponding to the 15 N-terminal amino acids
of human decorin (EDEASGIGPEVPDDR) containing Xyl attached
to Ser Oc (N-decorin-Xyl) was generated using the AMBER/
GLYCAM Input Conﬁgurator server (http://glycam.ccrc.uga.edu/
AMBER). Docking N-decorin-Xyl into b4GalT7 acceptor binding site
was performed manually based on the position of the ﬁrst N-acet-
yl-D-glucosamine in the structure of bovine b4GalT1 (PDB entry
1TW5), and this model was submitted to energy minimization
and molecular dynamics as described above. Finally, the model
of human b4GalT7 was compared to the crystal structure of
Drosophila b4GalT7 (PDB entry 3LW6) using the Dali program for
protein structure comparison available at http://ekhidna.biocenter.
helsinki.ﬁ/daliserver/ [24].2.9. Statistical analyses
All data are presented as mean ± S.D. of three determinations on
at least two sets of experiments. For comparison among multiple
groups, one-way analysis of variance (ANOVA) followed by Bonfer-roni post-hoc correction test was used. Statistical analyses were
performed using GraphPad Prism software (version 5.0).
3. Results
3.1. EDS mutants exhibit large differences in b4GalT7 activity and
kinetic properties
Wild-type b4GalT7, and A186D, L206P and R270C mutants were
expressed as full-length proteins in CHO pgsB-618 cells and tested
for in vitro galactosyltransferase activity using 4-MUX as acceptor
substrate. Fig. 1 revealed large differences in galactosyltransferase
activity between wild-type and mutant enzymes, although the re-
combinant proteins were expressed at similar level, as indicated by
immunoblot analysis using anti-myc antibodies (not shown). The
b4GalT7-A186D mutant exhibited nine-times lower activity than
wild-type, whereas substitution of Leu206 with Pro led to an inac-
tive enzyme. The b4GalT7-R270C mutant catalyzed the transfer of
Gal onto 4-MUX with a speciﬁc activity reaching about 60% that of
the wild-type enzyme.
To further analyze the kinetic properties of EDS-b4GalT7 mu-
tants, the catalytic domain of wild-type and mutant enzymes
was produced as a soluble protein fused to GST in E. coli. The
recombinant wild-type enzyme, and b4GalT7-A186D and R270C
mutants were puriﬁed to apparent homogeneity by afﬁnity chro-
matography (Fig. 2). Determination of the kinetic parameters of
the puriﬁed enzymes showed that the wild-type GST- b4GalT7
fusion protein was highly active with a kcat up to 1.1 s1 (Table 1).
Furthermore, the Km value of this enzyme towards UDP-Gal and
4-MUX was about 0.45 mM and 0.60 mM, respectively. These val-
ues are in the same range as apparent Km determined for the mem-
brane-bound enzyme expressed in HeLa cells (data not shown),
indicating that expression of the catalytic domain, i.e. lacking
the transmembrane domain and stem region did not substantially
affect substrate binding and catalytic properties of the enzyme. The
Km value for GST-b4GalT7 towards UDP-Gal was also in the same
range as reported by Pasek et al. [25], for the human b4GalT7
expressed in fusion with galectin (i.e. 0.51 mM).
Consistent with the low level of activity detected for the
b4GalT7-A186D mutant expressed in deﬁcient CHO cells, this var-
iant showed little activity when produced in bacteria, preventing
further kinetic analyses. The b4GalT7-L206P mutant, which lacked
activity in eukaryotic cells, was mainly produced as insoluble
inactive protein when expressed in E. coli (Fig. 2). These results
indicate that exchange of leucine at position 206 to a proline
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IPTG
L S2L PL S2L P L S2L P L S1L S2
75
100
50
37
25
kDa
- + - + - + - +
β4GalT7
Fig. 2. Expression and puriﬁcation of EDS-b4GalT7 mutants in E. coli. Wild-type GalT7 and mutated proteins were expressed in E. coli, and A186D, and R270C mutants were
puriﬁed from supernatant of 12000g centrifugation by afﬁnity chromatography. Proteins were analyzed by SDS–PAGE and stained with Coomassie Brilliant Blue. Shown
from left to right, cell lysate from uninduced and IPTG-induced bacteria (L, 25 lg), 12000g supernatant (S2, 12 lg) and puriﬁed fusion protein (P, 1–3 lg). S1 refers to
5000g supernatant from cell lysates expressing b4GalT7-L206P mutant.
β4GalT7 mock A186D L206P R270C
- + - + - + - + - +
14.3
66
45
30
220
97
2 1030 1 4 5 6 7 8 9
Concentration (μM)
5000
10000
9000
8000
7000
6000
4000
3000
2000
1000
0
dp
m
 / 
m
L 
m
ed
iu
m
β4GalT7
mock
A186D
L206P
R270C
kDa
4-MUX
Fig. 3. Kinetics of GAG chain synthesis from 4-MUX in CHO pgsB-618 cells
expressing wild-type or EDS-b4GalT7 mutants. Cells seeded at 6  105 cells in six-
well plates were individually transfected with pcDNA-b4GalT7 or A186D, L206P,
and R270C mutants. (A) Kinetics of GAG synthesis as a function of 4-MUX-
concentration. 24H following transfection, cells were incubated in the presence of
Na2[35SO4] and increasing concentrations of 4-MUX for 12 h before GAG isolation
and quantiﬁcation by scintillation counting. (B) Gel electrophoresis of radiolabelled
GAG chains isolated from conditioned medium of recombinant CHO pgsB-618 cells
incubated in the presence of Na2[35SO4] and 4-MUX (5 lM).
C. Bui et al. / FEBS Letters 584 (2010) 3962–3968 3965residue probably affected protein folding and dramatically im-
paired its function. In contrast, substitution of Arg270 to cysteine
resulted in a b4GalT7 protein which retained activity. Interestingly,
whereas the Km value of the b4GalT7-R270C mutant towards UDP-
Gal was similar to that of the wild-type enzyme, its afﬁnity for the
xyloside acceptor substrate 4-MUX was dramatically reduced (10-
times higher Km value compared to wild-type).
3.2. Molecular modelling of human b4GalT7
A molecular model of human b4GalT7 was built based on the
structure of bovine b4GalT1 in complex with UDP-Gal molecule
(PDB 1O0R). The position of A186, L206 and R270 are highlighted
in the structure is shown in Fig. 5, panel A. We also used the crystal
structure of the bovine b4GalT1 in complex with an oligosaccha-
ride acceptor substrate, as template (PDB 1TW5), to generate a
model of the human b4GalT7 acceptor binding site containing N-
decorin-Xyl. The results shown Fig. 5B suggest a potential interac-
tion between Arg270 and the serine residue of decorin peptide.
Furthermore, we carried out a superimposition of the modelled hu-
man b4GalT7 and of the crystal structure of Drosophila b4GalT7
(PDB 3LW6 [26]), by structure alignment using Dali program [24]
(Supplementary data, Fig. 1). The results show a Z-score of 22.8
and a RMSD (Root mean standard deviation) of 2.6 Å, indicating a
good ﬁt between the structures of modelled human and Drosophila
b4GalT7. The two structures exhibit a very similar organization of
the core protein with Ala186 and Leu206 (numbered in human
b4GalT7) located in a secondary structure environment similar to
that of Ala169 and Val189 (numbered in ﬂy b4GalT7) (Supplemen-
tary data, Fig. 1). On the other hand, Arg270 is located at the sur-
face of the protein, in a less conserved structural domain
between human and ﬂy b4GalT7 proteins. In the case of the protein
from Drosophila, this domain contains a disulﬁde bond between
Cys255 and Cys310 [26], which is not present in human, contribut-
ing to a different secondary structure of the C-terminal part of the
b4GalT7 protein compared to its human counterpart domain con-
taining Arg270.
3.3. Effect of EDS mutations on GAG synthesis in CHO pgsB-618 cells
We next designed a series of experiments to determine the
functional consequences of EDS mutations on b4GalT7 activity
ex vivo. For this purpose, we analyzed the capacity of wild-type
and mutated enzymes to prime GAG synthesis on the exogenous
b-D-xyloside 4-MUX, in b4GalT7-deﬁcient CHO pgsB-618 cells.
The rate of GAG synthesis was evaluated in recombinant cells asa function of xyloside concentration. Results shown in Fig. 3A indi-
cate that expression of wild-type b4GalT7 in these cells induced a
concentration-dependent increase in GAG synthesis. No detectable
[35SO4]-incorporation was detected in mock-transfected cells, up
to 10 lM 4-MUX concentration (Fig. 3A). In conﬁrmation of these
observations, SDS–PAGE analysis revealed the presence of radiola-
belled GAG chains in b4GalT7-transfected CHO psgB-618 cells
upon addition of 4-MUX, whereas no radioactivity could be de-
tected in mock-transfected cells, or when addition of xyloside
was omitted (Fig. 3B). Interestingly, although the b4GalT7-A186D
mutant exhibited low in vitro enzyme activity, this variant was
able to prime GAG synthesis in CHO deﬁcient cells up to a synthesis
rate reaching two-third that of the wild-type enzyme at the high-
est concentration of 4-MUX (Fig. 3A). The presence of radiolabelled
Fig. 4. Heparan-sulfate expression in CHO pgsB-618 cells transfected with EDS-b4GalT7 mutants. Cells were transfected with pcDNA-b4GalT7, A186D, L206P, or R270C or
mock-transfected and indirect immunoﬂuorescence staining was performed using 10E4 anti-heparan-sulfate (anti-HS, left panels), or following permeabilisation using anti-
myc antibodies (right panels). Nuclei were stained by Hoechst reagent prior to mounting slides.
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medium of cells transfected by this mutant in the presence of 4-
MUX (Fig. 3B). Furthermore, the b4GalT7-L206P mutant exhibited
no GAG priming activity towards 4-MUX in transfected cells, con-
sistent with the lack of galactosyltransferase activity observed for
this enzyme in vitro. In agreement, no radiolabelled GAG chains
were observed upon gel electrophoresis analysis in those cells, in
the presence of 4-MUX (Fig. 3). b4GalT7-R270C mutant was able
to produce a signiﬁcant increase in GAG synthesis rate as a func-
tion of 4-MUX concentration, although at a lower level compared
to the wild-type enzyme. This result is in agreement with the
in vitro kinetic properties of this mutant, which were characterized
by a strong decrease in afﬁnity towards xyloside acceptor substrate
and reduced efﬁciency compared to the wild-type b4GalT7.
To further determine the consequences of EDS mutations on
GAG synthesis, we carried out immunoﬂuorescence analyses of
heparan-sulfate expression in b4GalT7-defective CHO pgsB-618
cells transfected with the corresponding cDNAs, since it was previ-ously reported that wild-type CHO-K1 cells predominantly pro-
duce heparan-sulfate GAG chains [12]. A prominent staining of
cell membrane heparan-sulfates by 10E4 antibodies (anti-hepa-
ran-sulfate), was observed in CHO-pgsB-618 cells transfected with
wild-type b4GalT7, and this staining pattern was associated with
typical Golgi pattern of the recombinant protein revealed
with anti-myc antibodies (Fig. 4). As expected, no heparan-sulfate
expression could be detected in mock-transfected CHO pgsB-618
cells by indirect immunoﬂuorescence analysis. The intracellular
location of b4GalT7-A186D, and of b4GalT7-R270C mutant was
similar to that of the wild-type exhibiting typical Golgi staining
(Fig. 4). In addition, these mutants were able to restore heparan-
sulfate cell surface expression revealed by 10E4 antibodies, con-
ﬁrming ex vivo galactosyltransferase analyses indicating that they
were able to sustain, at least partially, GAG chain priming in deﬁ-
cient CHO cells. By contrast, although the b4GalT7-L206P mutant
was expressed, as shown by intracellular staining using anti-myc
antibodies, no membrane staining of cellular heparan-sulfate could
Fig. 5. Molecular modelling of human b4GalT7 structure. (A) The model of b4GalT7
based on bovine b4GalT1 in complex with UDP-Gal (PDB entry 1O0R) is shown in
‘‘ribbon” and of UDP-Gal in ‘‘sticks”. Positions of Ala186, Leu206 and Arg270 are
highlighted in ‘‘balls-and-sticks”. (B) The model of the acceptor binding site of
human b4GalT7. Protein N-decorin-Xyl in ‘‘sticks”. Hydrogen bonds between
Arg270 (b4GalT7) and the main chain of Ser5 attached to Xyl (N-decorin-Xyl) are
shown in green dotted lines.
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on GAG synthesis. Similar to previous report [4], expression of this
mutant exhibited a diffuse pattern (Fig. 4), suggesting altogether
that L206P substitution results in a conformational change of the
b4GalT7 protein, loss of activity and altered intracellular
trafﬁcking.
4. Discussion
Individuals affected by the progeroid-type EDS suffer from se-
vere clinical manifestations including craniofacial and skeletal
abnormalities, developmental retardation and aged appearance
[1]. Although detailed studies on the mechanisms of GAG altera-
tions contributing to the complex pathology of this genetic disor-
der have been carried out in skin ﬁbroblasts from affected
patients [5,6], the molecular basis underlying b4GalT7 deﬁciency
is not yet fully understood. Here, we investigated the molecular
consequences of progeroid-type EDS mutations A186D, L206P,
and R270C on (i) b4GalT7 enzyme activity and kinetic properties
in vitro, and (ii) ex vivo GAG chain synthesis in defective CHO
pgsB-618 cells. These approaches, combined with computer-aided
modelling of the structure of human b4GalT7 and its acceptor
binding site, allowed us to elucidate the mechanisms underlyingb4GalT7 functional defects in EDS congenital glycosylation disor-
der. The b4GalT7-deﬁcient CHO pgsB-618 line was transfected
with wild-type, A186D, L206P or R270C cDNA with the resulting
pattern of activities, (i) b4GalT7-A186D mutant exhibited about
10% activity of wild-type; (ii) mutation of leucine at position 206
to proline abolished activity; (iii) galactosyltransferase activity of
the b4GalT7-R270C mutant was reduced two-fold compared to
wild-type. To assess the functional consequences of the mutations
in CHO pgsB-618 transfected cells, we developed two approaches.
Firstly, we studied the effect of the supplementation of 4-MUX on
GAG synthesis. Secondly, we analyzed the restoration of heparan-
sulfate expression by indirect immunoﬂuorescence analysis. Ex
vivo kinetic studies of GAG synthesis revealed that expression of
the b4GalT7-A186D mutant partially restored GAG priming com-
pared to the wild-type enzyme. Immunostaining of heparan-sul-
fate chains in b4GalT7-A186D transfected cells also revealed a
pattern similar to that observed upon expression of the wild-type
enzyme. These observations corroborate previous report indicating
that this mutant restored GAG synthesis based on ﬂow cytometry
analysis [4]. It should be noted that the reduction in b4GalT7 galac-
tosyltransferase activity in vitro due to the A186D substitution was
greater than the decrease in GAG priming evaluated in the CHO
pgsB-618. Interestingly, it was reported that this mutation caused
a larger reduction in apparent Km of b4GalT7 towards UDP-Gal
than acceptor substrate [10]. Since UDP-Gal serves as a sugar donor
for several galactosyltransferases involved in glycoprotein and
GAG synthesis, the concentration of this molecule might not been
rate-limiting, thus possibly explaining the moderate effect of the
b4GalT7-A186D mutation ex vivo.
Comparison of the consequences of the three genetic mutations
of b4GalT7 causing the progeroid form of EDS revealed that only
substitution of leucine at position 206 with proline, led to a com-
plete loss of enzyme activity. Our results showed that this mutant
was unable to prime GAG synthesis from exogenous xyloside 4-
MUX, nor restore heparan-sulfate expression in CHO pgsB-618
defective cells. Molecular modelling of the human b4GalT7 protein,
comparison of this model to the crystal structure of the Drosophila
b4GalT7 [26], and multiple sequence alignment studies provide
clues to explain this effect. Indeed, Leu206 is strongly conserved
in b4GalT7-related sequences among various animal species (Tal-
haoui, I., Oriol, R. et al. unpublished). In our model of the human
b4GalT7 structure (see Fig. 5A), this residue is positioned in a small
conserved b-sheet, similarly to its counterpart Val189 in Drosoph-
ila b4GalT7 3D structure (see Fig. 1 Supplementary data). Introduc-
tion of a proline residue at this position has been predicted to
disrupt the secondary or even the tertiary structure of the protein
[26]. In agreement with this assumption, we found that in contrast
to other EDS mutants, the catalytic domain of b4GalT7-L206P was
expressed as insoluble inactive material in E. coli.
It was previously shown by Seidler et al. [5] that b4GalT7 activ-
ity towards para-nitrophenyl-Xyl in skin ﬁbroblasts of patient har-
bouring the R270D mutation was reduced compared to ﬁbroblasts
from healthy patients. In agreement with this ﬁnding, comparison
of in vitro and ex vivo activity of b4GalT7-R270C mutant expressed
in CHO pgsB-618-defective cells showed a decrease of both in vitro
galactosyltransferase activity and GAG priming. Investigation of
the kinetic properties of the puriﬁed mutant enzyme following
expression in E. coli shed light on the biochemical basis of
b4GalT7-altered function upon mutation. A large decrease in afﬁn-
ity towards 4-MUX acceptor substrate was noticed for this mutant,
suggesting that arginine to cysteine replacement at position 270
may alter the organization of the acceptor binding site. An increase
in Km value upon R270C mutation was also observed when using a
synthetic glycine-serine-Xyl derivative as acceptor substrate (data
not shown). Interestingly, molecular modelling of b4GalT7 bound
to Xyl attached to the serine of a decorin peptide predicted that
3968 C. Bui et al. / FEBS Letters 584 (2010) 3962–3968Arg270 is located in the vicinity of the core protein of this proteo-
glycan (Fig. 5B), which glycanation is affected in EDS [5]. In the
Drosophila structure, it has been found that Lys254 (corresponding
to Arg270 in primary sequence alignment) is located at the C-ter-
minal end of the long ﬂexible loop (residues 242–255), and the
authors predicted that a cysteine substitution may affect the con-
formational ﬂexibility of this loop [26]. Noteworthy, protein com-
parison of the C-terminal domain containing Arg270 indicates
that human and Drosophila b4GalT7 structures present a different
secondary structure organization. Therefore, crystal structure reso-
lution of the human b4GalT7 in complex with acceptor substrate is
required to deﬁnitively establish the consequences of R270C-EDS
mutation.
In conclusion, based on current results, we propose the follow-
ing molecular basis underlying progeroid type EDS. (1) Although
the Ala186 to aspartate replacement strongly reduced in vitro
b4GalT7 enzyme activity when expressed in deﬁcient-CHO pgsB-
618 cells and in E. coli, the consequences of this mutation on
GAG synthesis are much less pronounced. This ﬁnding suggests
that this mutation is not the primary cause for the alteration of
GAG synthesis observed in the EDS patient carrying the compound
A186D and L206P mutations. (2) In contrast, the dramatic effect of
L206P both on in vitro and ex vivo b4GalT7 activity can be attrib-
uted to a major conformational change induced by the leucine to
proline substitution at this position. This is likely to account for
the alteration of GAG synthesis in the progeroid EDS patient carry-
ing the compound mutations. (3) The b4GalT7-R270C mutant
exhibited a strong decrease in afﬁnity together with a decreased
catalytic efﬁciency that translated into a reduced ability to prime
GAG synthesis upon expression in b4GalT7-deﬁcient cells. These
molecular alterations are likely to cause the altered GAG structure
and connective tissue disorder observed in the patient carrying a
homozygous mutation of b4GalT7 at this position.
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